Association of anti-E1E2 antibodies with spontaneous recovery or sustained viral response to therapy in patients infected with hepatitis C virus
✍ Scribed by Ndiémé Ndongo; Pascale Berthillon; Pierre Pradat; Claude Vieux; Isabelle Bordes; Françoise Berby; Marianne Maynard; Fabien Zoulim; Christian Trépo; Marie-Anne Petit
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 625 KB
- Volume
- 52
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Interferon (IFN) alfa has been used widely for the treatment of chronic hepatitis C virus (HCV) infections but only a small number of patients treated have shown a sustained biochemical and virological response. Anti-envelope E1 and E2 antibody titers were assessed retrospectively before, during, an
## Abstract Variation at the IL‐28B locus was recently reported to be a significant predictive factor of viral response to pegylated‐interferon plus ribavirin combination therapy against chronic hepatitis C. Predictive factors for the effect of therapy, including IL‐28B polymorphism rs8099917 and v
## Abstract Heterogeneity of subgenomic regions of hepatitis C virus (HCV) may be associated with response to interferon (IFN) therapy. The amino acid sequences of the PKR/eIF‐2α phosphorylation homology domain (pePHD), IFN sensitivity determining region (ISDR), PKR binding domain (PKRBD), and vari
## Abstract For chronic hepatitis C virus (HCV) infection, evaluation of response to peginterferon (PEG‐IFN) plus ribavirin (RBV) therapy based on viral kinetics is useful as an early predictor of treatment efficacy, but the underlying mechanisms of the different viral kinetics to treatment are sti
## Abstract Patients with high viral load (≥1.0 × 10^5^ IU/ml) of hepatitis C virus (HCV) genotype 1b do not achieve high sustained virological response rates to interferon (IFN)/ribavirin combination therapy. Previous studies suggested that pretreatment amino acid (aa) substitution patterns in the